Epinastine

Drug Profile

Epinastine

Alternative Names: Alesion Tablet; Flurinol; Talerc; WAL 801; WAL 801 CL

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Class Antiallergics; Dibenzazepines; Imidazoles; Nonsedating antihistamines; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Allergic rhinitis; Asthma; Atopic dermatitis; Dermatitis; Psoriasis; Urticaria

Most Recent Events

  • 01 Aug 2005 Sankyo has terminated its licence for Epinastine in Japan
  • 23 Mar 2005 Alesion Dry Syrup has been launched in Japan for the treatment of allergic rhinitis, urticaria and pruritus
  • 27 Jan 2005 Alesion® Dry Syrup has received manufacturing approval in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top